Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Jin-Wook Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Surveillance Rate and its Impact on Survival of Hepatocellular Carcinoma Patients in South Korea: A Cohort Study
Sanghyuk Im, Eun Sun Jang, Ju Hyun Lee, Chung Seop Lee, Beom Hee Kim, Jung Wha Chung, Jin-Wook Kim, Sook-Hyang Jeong
Cancer Res Treat. 2019;51(4):1357-1369.   Published online February 12, 2019
DOI: https://doi.org/10.4143/crt.2018.430
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Though regular surveillance of hepatocellular carcinoma (HCC) for high-risk patients is widely recommended, its rate and effectiveness are not clear. The aim of this study is to investigate the actual rate of HCC surveillance and its related factors and to clarify its impact on survival in a Korean HCC cohort.
Materials and Methods
From 2012 to 2015, 319 newly diagnosed HCC patients were prospectively enrolled at a tertiary hospital. Patient interviews based on a structured questionnaire survey were conducted. Surveillance was defined as liver imaging test ≥ 2 times with at least 3-month interval within 2 years prior to HCC diagnosis.
Results
Surveillance rate was 39.8%. Of the HCC patients with high-risk factors, only 182 (57.1%) had knowledge for the need for regular surveillance, and 141 (44.2%) had the accurate information about the method (ultrasound-based study). Surveillance group showed a higher proportion of early HCC (p < 0.001) and a longer overall survival (p < 0.001) compared to non-surveillance group. The multivariable Cox regression analysis indicated Child-Pugh class A, history of anti-viral therapy, low serum α-fetoprotein level, non-advanced Barcelona Clinic Liver Cancer stage as independent predictors of overall survival, while regular surveillance was not (p=0.436).
Conclusion
Less than half of the newly diagnosed Korean HCC patients were under surveillance and the accurate perception for the need of HCC surveillance was insufficient. Of those under surveillance, most patients were diagnosed with early stage HCC, which led to the improved survival. Comprehensive efforts to optimize the surveillance program for the target population are warranted.

Citations

Citations to this article as recorded by  
  • Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: systematic review and meta-analysis
    Jichun Yang, Zhirong Yang, Xueyang Zeng, Shuqing Yu, Le Gao, Yu Jiang, Feng Sun
    Journal of the National Cancer Center.2023; 3(3): 175.     CrossRef
  • Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data
    Min Jung Kwon, Soy Chang, Ji Hoon Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal
    Joo Hye Song, Myung Ji Goh, Yewan Park, Joo Hyun Oh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
    Scandinavian Journal of Gastroenterology.2021; 56(3): 274.     CrossRef
  • Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study
    Dong Hyun Sinn, Danbee Kang, Yun Soo Hong, Kwang Cheol Koh, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak, Luca Rinaldi
    PLOS ONE.2021; 16(8): e0255624.     CrossRef
  • 7,620 View
  • 212 Download
  • 6 Web of Science
  • 4 Crossref
Close layer
Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era
Nae Yu Kim, Jong Mu Sun, Yu-Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jin-Wook Kim, Sook-Hyang Jeong, Jong Seok Lee
Cancer Res Treat. 2010;42(4):203-209.   Published online December 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.4.203
AbstractAbstract PDFPubReaderePub
Purpose

Systemic chemotherapy is the only option for patients with unresectable/metastatic hepatocellular carcinoma (HCC) who are not candidates for local/regional treatment. However, the response to such treatment and survival are poor, especially in hepatitis B virus (HBV) endemic areas. The aim of this study was to determine the efficacy of cisplatin-based combination chemotherapy and identify a subgroup of advanced HCC patients with favorable responses.

Materials and Methods

The medical records of all consecutive patients with unresectable/metastatic HCC who received cisplatin-based combination chemotherapy between January 2003 and October 2009 were reviewed. Time to progression (TTP) and overall survival (OS) were determined using Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify prognostic factors for TTP and OS.

Results

Data for 46 patients were analyzed. First-line chemotherapies consisted of cisplatin-based combination treatment with doxorubicin, fluoropyrimidines and gemcitabine. The response rate for all patients was 4.3%. The median TTP and OS were 1.8 (95%confidence interval [CI], 1.1 to 2.5) and 7.2 (95% CI, 3.0 to 11.5) months, respectively. Eastern Cooperative Oncology Group (ECOG) performance status (PS), Child classification, Cancer of the Liver Italian Program (CLIP) score and portal vein thrombosis (PVT) were identified by univariate analyses as prognostic factors for TTP and OS. ECOG PS (hazard ratio [HR], 4.51; 95% CI, 1.61 to 12.6; p=0.004) and PVT (HR, 2.12; 95% CI, 1.10 to 4.11; p=0.026) were independent prognostic factors for TTP.

Conclusion

Cisplatin-based combination chemotherapy in patients with advanced HCC has a low response rate and short TTP regardless of the chemotherapy regimen used. Patients with a good ECOG PS and without PVT can be considered candidates for cisplatin-based combination chemotherapy.

Citations

Citations to this article as recorded by  
  • circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR‐338‐5p/IL‐7 pathway
    Siyu Zhang, Jun Ma, Tingdong Yu, Zhengrui Song, Wan Yee Lau, Yong Zha
    Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
  • Inhibition of mycobacteria proliferation in macrophages by low cisplatin concentration through phosphorylated p53-related apoptosis pathway
    Jiajia Bao, Yonglin He, Chun Yang, Nan Lu, Anlong Li, Sijia Gao, Felycia Fernanda Hosyanto, Jialing Tang, Junzhuo Si, Xia Tang, Huichao Fu, Lei Xu, Harish Chandra
    PLOS ONE.2023; 18(1): e0281170.     CrossRef
  • A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma
    Yao‐Chung Liu, Chien‐Wei Su, Po‐Shen Ko, Rheun‐Chuan Lee, Chia‐Jen Liu, Yi‐Hsiang Huang, Jyh‐Pyng Gau, Jin‐Hwang Liu
    Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 19.     CrossRef
  • A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy
    Vincent Manceau, Xavier Palard, Yan Rolland, March Pracht, Samuel Le Sourd, Sophie Laffont, Karim Boudjema, Astride Lievre, Habiba Mesbah, Laure-Anne Haumont, Laurence Lenoir, Vanessa Brun, Thomas Uguen, Julien Edeline, Etienne Garin
    European Journal of Nuclear Medicine and Molecular Imaging.2018; 45(10): 1731.     CrossRef
  • Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1
    Jun Qin, Meng Luo, Haixin Qian, Wei Chen
    Gene.2014; 538(2): 342.     CrossRef
  • The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines
    EUN-YOUNG MIN, IN-HYE KIM, JUNGIM LEE, EUN-YOUNG KIM, YOUN-HEE CHOI, TAEK-JEONG NAM
    International Journal of Oncology.2014; 45(1): 47.     CrossRef
  • The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation
    Vasilis P. Androutsopoulos, Demetrios A. Spandidos
    The Journal of Nutritional Biochemistry.2013; 24(2): 496.     CrossRef
  • Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan
    Hiroki Nishikawa, Yukio Osaki, Ryuichi Kita, Toru Kimura
    Cancers.2012; 4(1): 165.     CrossRef
  • 9,573 View
  • 55 Download
  • 8 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP